Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

[1]  S. Jalkanen,et al.  Vascular adhesion protein-1 is actively involved in the development of inflammatory lesions in rat models of multiple sclerosis , 2018, Journal of Neuroinflammation.

[2]  C. Hung,et al.  Inhibition of semicarbazide‐sensitive amine oxidase reduces atherosclerosis in apolipoprotein E‐deficient mice , 2018, Translational research : the journal of laboratory and clinical medicine.

[3]  K. Tsubota,et al.  Inhibition of Vascular Adhesion Protein‐1 for Treatment of Graft‐Versus‐Host Disease in Mice , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  S. Jalkanen,et al.  Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation , 2017, Antioxidants & redox signaling.

[5]  Tetsuhiro Tanaka,et al.  Vascular adhesion protein-1 enhances neutrophil infiltration by generation of hydrogen peroxide in renal ischemia/reperfusion injury. , 2017, Kidney international.

[6]  G. Laverman,et al.  Variability in response to albuminuria‐lowering drugs: true or random? , 2017, British journal of clinical pharmacology.

[7]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[8]  D. de Zeeuw,et al.  Unmet need in diabetic nephropathy: failed drugs or trials? , 2016, The lancet. Diabetes & endocrinology.

[9]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[10]  C. Hung,et al.  Serum Vascular Adhesion Protein-1 Predicts End-Stage Renal Disease in Patients with Type 2 Diabetes , 2016, PloS one.

[11]  J. Lewis,et al.  Albuminuria Is an Appropriate Therapeutic Target in Patients with CKD: The Pro View , 2015 .

[12]  A. Levey,et al.  Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. , 2015, JAMA.

[13]  C. Weston,et al.  Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis. , 2015, The Journal of clinical investigation.

[14]  R. Bilous,et al.  KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  Merlin C. Thomas,et al.  An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. , 2011, Kidney international.

[16]  John H. Zhang,et al.  Vascular Adhesion Protein-1 Inhibition Provides Antiinflammatory Protection after an Intracerebral Hemorrhagic Stroke in Mice , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  C. Hung,et al.  Serum Vascular Adhesion Protein-1 Predicts 10-Year Cardiovascular and Cancer Mortality in Individuals With Type 2 Diabetes , 2011, Diabetes.

[18]  M. O. oude Egbrink,et al.  Small-Molecule Inhibitors of Vascular Adhesion Protein-1 Reduce the Accumulation of Myeloid Cells into Tumors and Attenuate Tumor Growth in Mice , 2010, The Journal of Immunology.

[19]  Shyang-Rong Shih,et al.  Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[20]  Shyang-Rong Shih,et al.  Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. , 2008, Clinical biochemistry.

[21]  Joan W. Miller,et al.  Inhibition of vascular adhesion protein‐1 suppresses endotoxin‐induced uveitis , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  S. Jalkanen,et al.  The oxidase activity of vascular adhesion protein-1 (VAP-1) induces endothelial E- and P-selectins and leukocyte binding. , 2007, Blood.

[23]  S. Jalkanen,et al.  Cell-surface enzymes in control of leukocyte trafficking , 2005, Nature Reviews Immunology.